Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trega Biosciences Inc.

Division of Sygnis AG
www.lionbioscience.com

Latest From Trega Biosciences Inc.

Workforce Roundtable Part 3: Diversity And Progress – And Advice For Biopharma's Next Generation

Women in leadership roles has become a much discussed issue for the biopharma industry, but less attention seems to be focused on racial diversity. Scrip's panel talks about challenges and opportunities, and offers advice for next generation employees.

Human Capital Leadership

Workforce Roundtable Part 2: Creating A 'Sticky' Workplace, Boardroom Roles For Women, Millennials

Once you've created an attractive company culture for women and millennials, what else should be done to retain the next generation of biopharma leaders? For starters, Scrip's panelists say, give them opportunities to contribute – including in the boardroom - and be open to new ways of communication.

Human Capital Leadership

Workforce Roundtable Part 1: Recruiting Biopharma Leaders As The Talent Pool Shrinks And Diversifies

As Baby Boomers age out of the workforce, they'll be replaced in biopharma C-suites and boardrooms by a younger, more female and racially diverse group. A panel of current and former life science CEOs, venture investors and recruiters discuss the challenges and opportunities ahead.

Human Capital Leadership

ArQule Takes the Drug Discovery Plunge

Over the past two-and-one-half years, ArQule's new management has refocused the once divided company, and repaired its reputation in the eyes of the financial community. That leadership also decided that ArQule can reach its growth potential only by moving away from a fee-for-services model and becoming a full-fledged drug discovery company. It's a transition that few companies have successfully managed, in part because of the tough balancing act required to build the requisite R&D infrastructure, while devoting sufficient resources to the near-term activity needed to build that infrastructure. ArQule will likely try to acquire biology-based companies to gain control over its own targets, but must deal with the valuation imbalance that still favors genomics/biology firms. But ArQule's management believes that its technology platform--as enhanced by the addition of predictive ADMET modeling--will boost its ability to process target into targets and thus its value.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Houghten Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sygnis AG
  • Senior Management
  • Rudolph Potenzone, PhD, Pres. & CEO
    Alan Hillyard, PhD, SVP, Cheminformatics Research
    Mark Canales, PhD, SVP, Cheminformatics Dev.
  • Contact Info
  • Trega Biosciences Inc.
    Phone: (858) 410-6500
    9880 Campus Point Dr.
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register